Showing 8171-8180 of 8879 results for "".
- FDA Approves Braftovi in Combination with Mektovi for Advanced BRAF-mutant Melanomahttps://practicaldermatology.com/news/fda-approves-of-braftovi-in-combination-with-mektovi-for-advanced-braf-mutant-melanoma/2457710/The FDA has approved Array BioPharma Inc.'s BRAFTOVI (encorafenib) capsules in combination with MEKTOVI (binimetinib) tablets for the treatment of patients with unresectable or metastatic melanoma with a BRAFV600E or BRAFV600K mutation, as detected by a
- Older Melanoma Patients May Have Better Response to Immune Checkpoint Blockade Therapyhttps://practicaldermatology.com/news/older-melanoma-patients-may-have-better-response-to-immune-checkpoint-blockade-therapy/2457728/Patient age correlates with response to immunotherapy in melanoma, and depleting regulatory T cells in young patients may have a therapeutic potential to enhance response in younger patients, according to research from The Wistar Institute. Study resul
- Spironolactone May Be an Alternative to Antibiotics in Female Acnehttps://practicaldermatology.com/news/spironolactone-may-be-an-alternative-to-antibiotics-in-female-acne/2457738/The diuretic drug spironolactone may be just as effective as antibiotics for the treatment of women’s acne, report researchers from the Perelman School of Medicine at the University of Pennsylvania. The study, published in the Journal of
- Rapamycin Lotion Reduces Facial Tumors Caused by Tuberous Sclerosishttps://practicaldermatology.com/news/rapamycin-lotion-reduces-facial-tumors-caused-by-tuberous/2457750/Rapamycin lotion significantly reduced the disfiguring facial tumors affecting more than 90 percent of people with tuberous sclerosis complex (TSC), researchers from The University of Texas Health Science Center at Houston (UTHealth) report. Findings of the multicenter, international stud
- Acne Survey at Twins Convention Affirms Genetic Linkhttps://practicaldermatology.com/news/acne-survey-at-twins-convention-affirms-genetic-link/2457789/A survey of identical and fraternal twin pairs at the Twins Days Festival in Twinsburg, OH, and published in the April issue of the Journal of Drugs in Dermatology, shows acne may be primarily caused by genetics.
- Kiwi Skincare Line Comes to US Ulta Storeshttps://practicaldermatology.com/news/kiwi-skincare-line-comes-to-us-ulta-stores/2457793/
- Cellulite Market Expected to Growhttps://practicaldermatology.com/news/cellulite-market-expected-to-grow/2457792/The cellulite treatment market is expected to grow worldwide, as the obesity epidemic grows. Findings are in the comprehensive research report by Future Market Insights entitled “Cellulite Treatment Market
- Physician Assistant Groups Respond to JAMA Dermatology Study: "Fundamentally Flawed"https://practicaldermatology.com/news/physician-assistant-groups-respond-to-jama-dermatology-study-fundamentally-flawed/2457798/The American Academy of PAs (AAPA) and the Society of Dermatology PAs (SDPA) have issued a statemen
- Aclaris Partners with Cipher to Seek Approval and Commercialize A-101 40% for Seborrheic Keratoses in Canadahttps://practicaldermatology.com/news/aclaris-partners-with-cipher-to-seek-approval-and-commercialize-a-101-40-for-seborrheic-keratoses-in-canada/2457814/Aclaris Therapeutics, Inc., has licensed the Canadian rights to commercialize A-101 40% topical solution for the treatment of raised seborrheic keratoses (A-101 40%) to Cipher Pharmaceuticals. A-101 40% was FDA approved in December 2017 and is marketed by Aclaris in the U.S. under the tradename E
- ASDSA Applauds USPSTF Endorsement of Behavioral Counseling to Prevent Skin Cancerhttps://practicaldermatology.com/news/asdsa-applauds-uspstf-endorsement-of-behavioral-counseling-to-prevent-skin-cancer/2457820/The American Society for Dermatologic Surgery Association (ASDSA) applauds the recent US Preventive Service Task Force (USPSTF) endorsement of behavioral counseling to prevent skin cancer for individuals aged six months to 24 years